Abstract PD04-02: Clinical Value of Circulating Tumor Cells (CTC) in First Line Metastatic Breast Cancer (MBC) Patients (pts) According to Type of Treatment and Immunohistochemical Molecular Subtype

Antonio Giordano(University of Siena), Massimo Cristofanilli(Cornell University), Mario Giuliano(Regione Campania), Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), BC Handy(Fox Chase Cancer Center), G. N. Hortobagyi(The University of Texas MD Anderson Cancer Center), JM Reuben(Fox Chase Cancer Center), Eleni Andreopoulou(Cornell University), EN Cohen(Fox Chase Cancer Center), RH Alvarez(Fox Chase Cancer Center)
Cancer Research
December 1, 2010
10.1158/0008-5472.sabcs10-pd04-02
Cited by 3

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Curcumin and Cancer
|Nutrients|2019|977